Myokardia Inc (MYOK) Insider Anastasios Gianakakos Sells 3,000 Shares
Myokardia Inc (NASDAQ:MYOK) insider Anastasios Gianakakos sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $41.70, for a total value of $125,100.00. Following the completion of the transaction, the insider now owns 512,117 shares of the company’s stock, valued at $21,355,278.90. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Anastasios Gianakakos also recently made the following trade(s):
- On Thursday, December 21st, Anastasios Gianakakos sold 3,000 shares of Myokardia stock. The shares were sold at an average price of $41.09, for a total value of $123,270.00.
- On Monday, November 6th, Anastasios Gianakakos sold 4,300 shares of Myokardia stock. The shares were sold at an average price of $40.23, for a total value of $172,989.00.
Myokardia Inc (MYOK) traded up $0.30 during trading hours on Friday, reaching $42.30. The company’s stock had a trading volume of 242,732 shares, compared to its average volume of 447,090. Myokardia Inc has a 52-week low of $10.55 and a 52-week high of $49.55. The firm has a market cap of $1,510.00 and a P/E ratio of -57.16.
Myokardia (NASDAQ:MYOK) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.42). Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The firm had revenue of $5.63 million during the quarter, compared to the consensus estimate of $6.10 million. During the same quarter in the prior year, the firm posted ($0.35) EPS. The business’s revenue was up 58.6% on a year-over-year basis. analysts expect that Myokardia Inc will post -1.62 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in MYOK. Nationwide Fund Advisors raised its stake in shares of Myokardia by 36.3% during the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 2,591 shares in the last quarter. Alliancebernstein L.P. bought a new stake in shares of Myokardia during the 2nd quarter worth approximately $148,000. State of Wisconsin Investment Board bought a new stake in shares of Myokardia during the 2nd quarter worth approximately $157,000. The Manufacturers Life Insurance Company raised its stake in shares of Myokardia by 38.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,073 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 4,215 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Myokardia during the 3rd quarter worth approximately $202,000. Institutional investors own 63.61% of the company’s stock.
Several equities analysts recently issued reports on the company. Zacks Investment Research lowered Myokardia from a “hold” rating to a “sell” rating in a research report on Wednesday. Wedbush reiterated an “outperform” rating and issued a $51.00 price objective on shares of Myokardia in a research report on Wednesday, September 20th. BidaskClub raised Myokardia from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. ValuEngine downgraded Myokardia from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, JPMorgan Chase & Co. assumed coverage on Myokardia in a research report on Tuesday, December 12th. They set an “overweight” rating and a $54.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $54.83.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/myokardia-inc-myok-insider-anastasios-gianakakos-sells-3000-shares/1797960.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with Analyst Ratings Network's FREE daily email newsletter.